A detailed history of Captrust Financial Advisors transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Captrust Financial Advisors holds 24,024 shares of CRSP stock, worth $1.24 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
24,024
Previous 25,443 5.58%
Holding current value
$1.24 Million
Previous $1.73 Million 25.2%
% of portfolio
0.0%
Previous 0.01%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$51.17 - $68.18 $72,610 - $96,747
-1,419 Reduced 5.58%
24,024 $1.3 Million
Q1 2024

May 15, 2024

SELL
$60.67 - $89.12 $75,655 - $111,132
-1,247 Reduced 4.67%
25,443 $1.73 Million
Q4 2023

Feb 14, 2024

BUY
$38.62 - $72.18 $34,024 - $63,590
881 Added 3.41%
26,690 $1.67 Million
Q3 2023

Nov 14, 2023

BUY
$45.39 - $59.0 $71,353 - $92,748
1,572 Added 6.49%
25,809 $1.17 Million
Q2 2023

Aug 14, 2023

SELL
$43.47 - $67.77 $74,724 - $116,496
-1,719 Reduced 6.62%
24,237 $1.36 Million
Q1 2023

May 15, 2023

SELL
$41.0 - $56.12 $10,496 - $14,366
-256 Reduced 0.98%
25,956 $1.17 Million
Q4 2022

Feb 15, 2023

BUY
$39.19 - $65.67 $27,472 - $46,034
701 Added 2.75%
26,212 $1.07 Million
Q3 2022

Nov 16, 2022

BUY
$61.1 - $83.78 $105,519 - $144,688
1,727 Added 7.26%
25,511 $1.67 Million
Q2 2022

Aug 23, 2022

SELL
$43.23 - $73.83 $148,019 - $252,793
-3,424 Reduced 12.58%
23,784 $1.45 Million
Q2 2022

Aug 16, 2022

BUY
$43.23 - $73.83 $269,063 - $459,517
6,224 Added 29.66%
27,208 $1.65 Million
Q1 2022

May 16, 2022

SELL
$53.19 - $79.24 $212,760 - $316,960
-4,000 Reduced 16.01%
20,984 $1.32 Million
Q4 2021

Feb 14, 2022

BUY
$70.09 - $111.29 $526,936 - $836,678
7,518 Added 43.04%
24,984 $1.89 Million
Q3 2021

Nov 16, 2021

SELL
$110.2 - $156.64 $415,784 - $591,002
-3,773 Reduced 17.76%
17,466 $1.96 Million
Q2 2021

Aug 16, 2021

SELL
$100.84 - $161.89 $81,781 - $131,292
-811 Reduced 3.68%
21,239 $3.44 Million
Q1 2021

May 17, 2021

BUY
$110.72 - $210.04 $531,123 - $1.01 Million
4,797 Added 27.8%
22,050 $2.69 Million
Q4 2020

Feb 16, 2021

SELL
$79.67 - $173.23 $17,925 - $38,976
-225 Reduced 1.29%
17,253 $2.64 Million
Q3 2020

Nov 17, 2020

SELL
$78.5 - $100.64 $137,139 - $175,818
-1,747 Reduced 9.09%
17,478 $1.46 Million
Q2 2020

Aug 14, 2020

BUY
$38.5 - $76.05 $27,373 - $54,071
711 Added 3.84%
19,225 $1.51 Million
Q1 2020

May 15, 2020

BUY
$33.68 - $62.53 $127,142 - $236,050
3,775 Added 25.61%
18,514 $713,000
Q4 2019

Feb 14, 2020

BUY
$36.68 - $73.13 $503,946 - $1 Million
13,739 Added 1373.9%
14,739 $874,000
Q1 2019

May 15, 2019

BUY
$28.02 - $40.87 $28,020 - $40,870
1,000 New
1,000 $36,000
Q3 2018

Nov 15, 2018

SELL
$44.35 - $65.71 $3,592 - $5,322
-81 Closed
0 $0
Q2 2018

Aug 13, 2018

BUY
$42.62 - $73.59 $3,452 - $5,960
81 New
81 $5,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $4.03B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.